Our top pick for
Replimune Group Inc is a biotechnology business based in the US. Replimune Group shares (REPL) are listed on the NASDAQ and all prices are listed in US Dollars. Replimune Group employs 152 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$29.01|
|52-week range||$27.66 - $54.85|
|50-day moving average||$31.42|
|200-day moving average||$33.07|
|Wall St. target price||$55.22|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.84|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-3.78%|
|1 month (2021-09-24)||-10.07%|
|3 months (2021-07-23)||-12.06%|
|6 months (2021-04-23)||-7.93%|
|1 year (2020-10-23)||-35.82%|
|2 years (2019-10-23)||96.41%|
|3 years (2018-10-23)||144.60%|
|5 years (2016-10-20)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-12.69%|
|Return on equity TTM||-23.97%|
|Market capitalisation||$1.4 billion|
TTM: trailing 12 months
There are currently 2.1 million Replimune Group shares held short by investors – that's known as Replimune Group's "short interest". This figure is 1% up from 2.1 million last month.
There are a few different ways that this level of interest in shorting Replimune Group shares can be evaluated.
Replimune Group's "short interest ratio" (SIR) is the quantity of Replimune Group shares currently shorted divided by the average quantity of Replimune Group shares traded daily (recently around 214646.02683179). Replimune Group's SIR currently stands at 9.69. In other words for every 100,000 Replimune Group shares traded daily on the market, roughly 9690 shares are currently held short.
However Replimune Group's short interest can also be evaluated against the total number of Replimune Group shares, or, against the total number of tradable Replimune Group shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Replimune Group's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Replimune Group shares in existence, roughly 40 shares are currently held short) or 0.0811% of the tradable shares (for every 100,000 tradable Replimune Group shares, roughly 81 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Replimune Group.
Find out more about how you can short Replimune Group stock.
We're not expecting Replimune Group to pay a dividend over the next 12 months.
Over the last 12 months, Replimune Group's shares have ranged in value from as little as $27.66 up to $54.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Replimune Group's is 2.4628. This would suggest that Replimune Group's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Replimune Group, Inc. , a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.